Raloxifene Tablets
Designed to support bone density, utilized to mitigate the risk of fractures in postmenopausal women by targeting oestrogen pathways.
- Categories
- Women's Health · Bone Health
- Active ingredient
- Raloxifene
- Supply
- Rx
- Route
- Oral use
- Form
- Film-coated tablet
- Strengths
- 60mg
Raloxifene Tablets details
- Condition
- Osteoporosis
- Alternative names
- Evista
- Therapeutic class
- Selective oestrogen Receptor Modulator
- Pharmacological class
- SERM
- Precautions and warnings
- discontinue before prolonged immobilisation; monitor for signs of blood clots
- Minor side effects
- hot flushes; leg cramps
- Moderate side effects
- peripheral oedema; flu-like symptoms
- Dosage forms
- Film-coated tablet
- Administration route
- Oral use
- Supply category
- Prescription only (specially controlled medicine)
- Manufacturer
- Daiichi Sankyo
- Onset Time
- 3–6 months
- Duration
- Ongoing
- Storage instructions
- Store in a cool, dry place.
- Drug interactions
- warfarin; cholestyramine
- Age restrictions
- Limited to postmenopausal women.
Contraindications
history of venous thromboembolism; hepatic impairment; severe renal impairment; uterine bleeding; pregnancy
Serious side effects
deep vein thrombosis, requires immediate medical attention; pulmonary embolism, requires immediate medical attention; stroke, requires immediate medical attention
Patient summary
designed to support bone density, utilized to mitigate the risk of fractures in postmenopausal women by targeting oestrogen pathways.
Mechanism of action
A selective oestrogen receptor modulator that mimics the beneficial effects of oestrogen on bone tissue while inhibiting its effects on breast and uterine tissue.
Pregnancy and breastfeeding
Pregnancy: Contraindicated; may cause harm to the foetus. Breastfeeding: Not applicable.
Where this medicine is registered
- Singapore
- Hong Kong
- Thailand
- Malaysia
- Philippines
- Indonesia
- Taiwan
- South Korea
- Japan
- Australia
- New Zealand
- UAE
- South Africa
About Raloxifene Tablets
Raloxifene is the active ingredient in Raloxifene Tablets, a standard treatment option for osteoporosis. Often recognised by its primary brand name Evista, it is frequently used to support long-term bone density. Supplied by Daiichi Sankyo, these tablets are available in a 60mg strength, providing a standard form for patients maintaining bone health.
Buying Raloxifene Tablets online
Raloxifene Tablets are registered across 14 markets globally, including South Korea, Japan and the UAE, with availability throughout Singapore, Hong Kong and Thailand. As a frequently ordered treatment for bone health across the region, generic versions of Raloxifene offer a cost-effective alternative to the original brand. Ordering online provides a reliable, convenient solution for expats and local residents who require consistent access to their ongoing treatment.